Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?
Oropharyngeal cancer
Quality of life
Radiotherapy
Recovery of function
Taste
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
07
01
2020
accepted:
20
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Taste impairment is a common radiation-induced toxicity in head and neck cancer (HNC) patients acutely. However, data on the potential for recovery and the time dependent course of late taste impairment are limited. As part of an IRB-approved observational prospective study, HNC patients underwent serial surveys including the MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN). For our analysis, we extracted MDASI-HN taste item results from oropharyngeal cancer patients treated with intensity-modulated radiotherapy or volumetric modulated arc therapy and at least two taste assessments after ≥1 year from end of radiotherapy (RT). 1214 MDASI taste items from 326 patients between 1 and 13 years post-RT were included. Median prescribed dose to the high-dose clinical target volume (CTV1) was 66.0 Gy, with 180 patients (55%) receiving chemotherapy. Taste markedly improved in the first years from end of RT, but plateaued after year 5. In patients with taste assessment in subsequent years, a significant reduction in taste impairment was found from the second to the third year (p = 0.001) and tended towards significance from the third to the fourth year (p = 0.058). Multivariate analysis revealed treatment site as significant factor in the sixth year from RT and CTV1 dose and age in the seventh year. Radiation-induced taste impairment may improve over an extended time interval, but becomes relatively stable from year 5 post-RT. Direct characterization of RT-induced taste impairment and the calculation of normal tissue complication probability should include consideration of the time-dependent course in taste recovery.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Taste impairment is a common radiation-induced toxicity in head and neck cancer (HNC) patients acutely. However, data on the potential for recovery and the time dependent course of late taste impairment are limited.
MATERIALS AND METHODS
METHODS
As part of an IRB-approved observational prospective study, HNC patients underwent serial surveys including the MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN). For our analysis, we extracted MDASI-HN taste item results from oropharyngeal cancer patients treated with intensity-modulated radiotherapy or volumetric modulated arc therapy and at least two taste assessments after ≥1 year from end of radiotherapy (RT).
RESULTS
RESULTS
1214 MDASI taste items from 326 patients between 1 and 13 years post-RT were included. Median prescribed dose to the high-dose clinical target volume (CTV1) was 66.0 Gy, with 180 patients (55%) receiving chemotherapy. Taste markedly improved in the first years from end of RT, but plateaued after year 5. In patients with taste assessment in subsequent years, a significant reduction in taste impairment was found from the second to the third year (p = 0.001) and tended towards significance from the third to the fourth year (p = 0.058). Multivariate analysis revealed treatment site as significant factor in the sixth year from RT and CTV1 dose and age in the seventh year.
CONCLUSION
CONCLUSIONS
Radiation-induced taste impairment may improve over an extended time interval, but becomes relatively stable from year 5 post-RT. Direct characterization of RT-induced taste impairment and the calculation of normal tissue complication probability should include consideration of the time-dependent course in taste recovery.
Identifiants
pubmed: 32373720
doi: 10.1016/j.ctro.2020.03.006
pii: S2405-6308(20)30019-7
pmc: PMC7191583
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98-105Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214825
Pays : United States
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Organisme : NIDCR NIH HHS
ID : R56 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097007
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028290
Pays : United States
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Curr Treat Options Oncol. 2018 Nov 9;19(12):72
pubmed: 30411162
Qual Life Res. 2016 Jun;25(6):1495-504
pubmed: 26589527
Cancer Treat Rev. 2015 Feb;41(2):179-86
pubmed: 25499998
J Neurosci. 2012 Mar 7;32(10):3474-84
pubmed: 22399770
J Pharm Bioallied Sci. 2014 Jul;6(Suppl 1):S30-3
pubmed: 25210380
Head Neck. 2014 Nov;36(11):1604-10
pubmed: 24115115
Radiother Oncol. 2016 May;119(2):213-20
pubmed: 27165613
Radiat Oncol. 2017 Sep 9;12(1):150
pubmed: 28888224
Oral Oncol. 2013 Jun;49(6):634-42
pubmed: 23562564
Ann Otol Rhinol Laryngol. 2017 Jul;126(7):548-554
pubmed: 28511547
Support Care Cancer. 2015 Nov;23(11):3257-68
pubmed: 25851804
Ann Oncol. 2017 May 1;28(5):969-984
pubmed: 28327968
Radiother Oncol. 2012 Sep;104(3):343-8
pubmed: 22853852
Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):459-67
pubmed: 10772298
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14
pubmed: 27354125
Dysphagia. 2014 Dec;29(6):663-70
pubmed: 25115856
J Clin Oncol. 2012 May 20;30(15):1777-83
pubmed: 22508814
Pract Radiat Oncol. 2015 Jul-Aug;5(4):e299-308
pubmed: 25544553
Arch Otolaryngol Head Neck Surg. 1991 May;117(5):519-28
pubmed: 2021470
BMC Cancer. 2011 Apr 12;11:128
pubmed: 21486431
World J Otorhinolaryngol Head Neck Surg. 2018 Jun 28;4(1):11-28
pubmed: 30035257
Ann R Coll Surg Engl. 2011 Nov;93(8):591-5
pubmed: 22041234
Chem Senses. 2015 May;40(4):285-92
pubmed: 25800268
Strahlenther Onkol. 2015 Jun;191(6):501-10
pubmed: 25747264
JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):129-33
pubmed: 24337483
Chem Senses. 2019 May 29;44(5):319-326
pubmed: 30957861
Am J Clin Oncol. 2011 Oct;34(5):478-82
pubmed: 21537150
J Clin Oncol. 1999 Mar;17(3):1008-19
pubmed: 10071296
Cancer. 2014 Jul 1;120(13):1975-84
pubmed: 24711162
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6
pubmed: 11448365
Front Physiol. 2017 Mar 08;8:134
pubmed: 28337150
Head Neck. 2007 Oct;29(10):923-31
pubmed: 17358040
J Oral Maxillofac Surg. 2010 Sep;68(9):2164-8
pubmed: 20542366
Head Neck. 2012 Jun;34(6):797-804
pubmed: 22127786
Radiother Oncol. 2016 Feb;118(2):335-41
pubmed: 26777124
Radiother Oncol. 2015 Oct;117(1):132-8
pubmed: 26403258
Br J Radiol. 2011 Apr;84(1000):367-74
pubmed: 21415302
Head Neck. 1993 Nov-Dec;15(6):485-96
pubmed: 8253555
Arch Neurol. 2003 May;60(5):667-71
pubmed: 12756129
Eur J Oncol Nurs. 2018 Dec;37:43-50
pubmed: 30473050
Clin Oncol (R Coll Radiol). 2003 Jun;15(4):205-10
pubmed: 12846500
Indian J Cancer. 2017 Apr-Jun;54(2):447-452
pubmed: 29469076
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):981-91
pubmed: 17145528